Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 2/20 | 0.41 |
| ▸ | SKP1 | P63208 | 2/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30553374 | 1.00 | GPR119 (0.47) | GPR119DDB1CRBNADRA1APIK3CD | |
| SCHEMBL25325974 | 0.86 | GPR119 (0.47) | GPR119DDB1CRBNPIK3CDCKS1B | |
| SCHEMBL31532333 | 0.86 | GPR119 (0.47) | GPR119DDB1CRBNPIK3CDCKS1B | |
| SCHEMBL31308843 | 0.83 | DDB1 (0.43) | GPR119DDB1CRBNRET | |
| SCHEMBL25299074 | 0.83 | DDB1 (0.43) | GPR119DDB1CRBNRET | |
| SCHEMBL25252867 | 0.82 | GPR119 (0.43) | GPR119DDB1CRBNPIK3CDCKS1B | |
| SCHEMBL30553389 | 0.82 | GPR119 (0.43) | GPR119DDB1CRBNPIK3CDCKS1B | |
| SCHEMBL25292207 | 0.81 | DDB1 (0.44) | GPR119DDB1CRBNPIK3CDRET | |
| SCHEMBL25292320 | 0.81 | ACACB (0.43) | GPR119DDB1CRBNPIK3CDCKS1B | |
| SCHEMBL25319235 | 0.81 | GPR119 (0.57) | GPR119DDB1CRBNPIK3CDCKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | GPR119 1935/4885DDB1 2804/4885CRBN 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.